Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab plus azacitidine versus azacitidine plus placebo in untreated higher-risk myelodysplastic syndrome
NL-OMON52320Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Magrolimab + azacitidine with Azacitidine + placebo (2 arms). Primary endpoints: Complete remission rate and Overall survival. Started Jan 2022; status: completed.
02
Drugs
magrolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON52320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52320.